Molecular Pathology & Genetics | SGCB Research Initiative

Structural Biochemistry

The "House of Cards" Assembly Cascade

In healthy skeletal and cardiac myocytes, the sarcoglycan complex exists as a stoichiometric tetramer (α, β, γ, δ) that spans the lipid bilayer. It associates directly with dystrophin and the β-dystroglycan axis to dissipate mechanical shear stress during myofibrillar contraction.

β-Sarcoglycan Nucleation

Assembly within the endoplasmic reticulum is non-linear. Biochemical pulse-chase studies (Chan et al. J Cell Biol 1998, PMID: 9813094) demonstrate that β-sarcoglycan must first bind δ-sarcoglycan to create the core heterodimer scaffold. Without β-sarcoglycan, α and γ subunits cannot incorporate.

Consequence: Total absence of tetrameric complex at sarcolemma.

ERAD Degradation

Orphan sarcoglycan subunits (α, γ, δ) that fail to assemble into the stable tetramer are recognized as aberrant by endoplasmic reticulum quality control chaperones (BiP/GRP78, calnexin). They undergo polyubiquitination and retrotranslocation to the 26S proteasome for degradation.

Phenotype: Complete sarcoglycan deficiency despite normal SGCA, SGCG, SGCD genes.

Mechanical Rupture & Calpain

Deprived of the sarcoglycan shock absorber, the sarcolemma tears under standard eccentric loading. Extracellular calcium ([Ca²⁺] ~1–2 mM) floods into the myoplasm ([Ca²⁺] ~100 nM), triggering hyperactivation of μ-calpain (CAPN1) and m-calpain (CAPN2) which digest titin, nebulin, and troponin.

Outcome: Contractile breakdown, necrosis, and high dilated cardiomyopathy risk.

Sequencing & Variant Annotation

Compound Heterozygous Class 5 Pathogenic Profile

Comprehensive molecular analysis of the compound heterozygous variants identified in diagnostic massively parallel sequencing (Muscle v7 panel; PathWest report DGS-24-5187).

Allele 1 • Exon 3 • Cadherin-Like Fold Missense • Class 5

c.341C>T | p.(Ser114Phe)

ClinVar: VCV000042035 • RefSeq: NM_000232.5:c.341C>T

Structural Consequence: Serine 114 resides on an exposed loop of the β-sarcoglycan extracellular ectodomain. The substitution of a hydrophilic serine with a bulky, hydrophobic phenylalanine disrupts the local thermodynamic stability and tertiary folding of the ectodomain.

Cellular Fate: The protein is translated at physiological rates, but the folding defect triggers prolonged engagement with the ER quality control machinery (BiP/GRP78). It is retrotranslocated to the cytosol, ubiquitinated, and degraded via ERAD.

Crucial Therapeutic Benchmark: In vitro experiments (Soheili et al. Hum Mutat 2011, PMID: 22095924) confirm that Ser114Phe retains intrinsic binding affinity for α-, γ-, and δ-sarcoglycan. If pharmacological chaperones or proteostasis regulators assist its folding or allow it to escape ERAD, it successfully integrates into the sarcolemma.

Intervention Target: Pharmacological chaperones • Adenine Base Editing (ABE).

Allele 2 • Exon 4 • Premature Stop Nonsense (PTC) • Class 5

c.552T>G | p.(Tyr184*)

ClinVar: VCV000008713 • RefSeq: NM_000232.5:c.552T>G

Structural Consequence: Introduction of a premature termination codon (PTC; UAA) at codon 184 in exon 4, truncating 135 amino acids from the essential C-terminal domain required for δ-sarcoglycan interaction.

Cellular Fate: The presence of a premature stop codon >50–55 nucleotides upstream of the final exon-junction complex activates the Upf1/Upf2/Upf3 nonsense-mediated mRNA decay (NMD) pathway. Transcripts are rapidly degraded before translation, resulting in a functional null allele (0% protein expression).

Founder Mutation History: Originally characterized by Bönnemann et al. (Nat Genet 1995, PMID: 7581449) and Trabelsi et al. (2008). Homozygous or compound heterozygous carriers display severe childhood-onset proximal limb-girdle weakness and calf pseudohypertrophy.

Intervention Target: AAV cDNA replacement • Prime Editing • Translational Read-Through.

Next: Gene Therapy & CRISPR Horizons

Explore the SRP-9003 Phase 3 EMERGENE trial data and in vivo base editing feasibility.

View Gene Therapy & CRISPR →